Peter M. Schneider

Peter M. Schneider

Auto-generated profile, based on publicly available information

Peter M. Schneider

Institut für Rechtsmedizin, Medizinische Fakultät und Universitätsklinik, Universität zu Köln, Köln, Deutschland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2015 in Nature
Verified
Journal Article
Open access
PDF file
JGJulie George
Julie George
JLJing Shan Lim
Jing Shan Lim
SJSe Jin Jang
Se Jin Jang
YCYupeng Cun
Yupeng Cun
LOLuka Ozretić
Luka Ozretić
RTRoman K. Thomas
Roman K. Thomas
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Δex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.

2 September 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MPMartin Peifer
Martin Peifer
LFLynnette Fernández-Cuesta
Lynnette Fernández-Cuesta
MSMartin L Sos
Martin L Sos
JGJulie George
Julie George
DSDanila Seidel
Danila Seidel
RTRoman K Thomas
Roman K Thomas

27 April 2006 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
JSJuan J. Sanchez
Juan J. Sanchez
CPChristopher Phillips
Christopher Phillips
Claus BørstingClaus Børsting
Claus Børsting
KBKinga Balogh
Kinga Balogh
MBMagdalena Bogus
Magdalena Bogus
Niels MorlingNiels Morling
Niels Morling

13 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJulie George
Julie George
VWVonn Walter
Vonn Walter
MPMartin Peifer
Martin Peifer
LALudmil B. Alexandrov
Ludmil B. Alexandrov
DSDanila Seidel
Danila Seidel
RTRoman K. Thomas
Roman K. Thomas
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung cancers, but their precise relationship has remained unclear. Here we perform a comprehensive genomic (n = 60) and transcriptomic (n = 69) analysis of 75 LCNECs and identify two molecular subgroups: “type I LCNECs” with bi-allelic TP53 and STK11/KEAP1 alterations (37%), and “type II LCNECs” enriched for bi-allelic inactivation of TP53 and RB1 (42%). Despite sharing genomic alterations with adenocarcinomas and squamous cell carcinomas, no transcriptional relationship was found; instead LCNECs form distinct transcriptional subgroups with closest similarity to SCLC. While type I LCNECs and SCLCs exhibit a neuroendocrine profile with ASCL1high/DLL3high/NOTCHlow, type II LCNECs bear TP53 and RB1 alterations and differ from most SCLC tumors with reduced neuroendocrine markers, a pattern of ASCL1low/DLL3low/NOTCHhigh, and an upregulation of immune-related pathways. In conclusion, LCNECs comprise two molecularly defined subgroups, and distinguishing them from SCLC may allow stratified targeted treatment of high-grade neuroendocrine lung tumors.

1 March 2006 in Forensic Science International
Verified
Journal Article
Closed access
LGLeonor Gusmão
Leonor Gusmão
JBJ.M. Butler
J.M. Butler
ÁCÁngel Carracedo
Ángel Carracedo
PGP. Gill
P. Gill
MKM. Kayser
M. Kayser
PSP.M. Schneider
P.M. Schneider

1 July 2006 in Forensic Science International
Verified
Journal Article
Closed access
PGP Gill
P Gill
CBC H Brenner
C H Brenner
JBJ S Buckleton
J S Buckleton
ÁCÁngel Carracedo
Ángel Carracedo
MKM Krawczak
M Krawczak
DGDNA commission of the International Society of Forensic Genetics
DNA commission of the International Society of Forensic Genetics